Vaccinex ( (VCNX) ) has released a notification of late filing.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Vaccinex, Inc., a biotechnology company, has announced a delay in filing its Form 10-K (Yearly Report) for the financial period ending December 31, 2024. The primary reason for the delay is the company’s difficulty in completing its financial statements for the year, which could not be resolved without unreasonable effort or expense. Vaccinex expects to file the report within the 15-day extension period allowed under Rule 12b-25. The company does not anticipate any significant changes in its financial results compared to the previous fiscal year. Vaccinex remains committed to compliance and has ensured all other required reports have been filed. The notification was signed by Jill Sanchez, the Chief Financial Officer.
More about Vaccinex
YTD Price Performance: -19.89%
Average Trading Volume: 4,525
Technical Sentiment Signal: Buy
Current Market Cap: $1.95M
Find detailed analytics on VCNX stock on TipRanks’ Stock Analysis page.